bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table and Figures from Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies
Authors: Chung David J. , Shah Gunjan L. , Devlin Sean M. , Ramanathan Lakshmi V. , Doddi Sital , Pessin Melissa S. , Hoover Elizabeth , Marcello LeeAnn T. , Young Jennifer C. , Boutemine Sawsan R. , Serrano Edith , Sharan Saumya , Momotaj Saddia , Margetich Lauren , Bravo Christina D. , Papanicolaou Genovefa A. , Kamboj Mini , Mato Anthony R. , Roeker Lindsey E. , Hultcrantz Malin , Mailankody Sham , Lesokhin Alexander M. , Vardhana Santosha A. , Knorr David A.
Published: April 2023

Figures S1- S4
Supplementary Figure S3 from Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma
Authors: Ohguchi Hiroto , Park Paul M.C. , Wang Tingjian , Gryder Berkley E. , Ogiya Daisuke , Kurata Keiji , Zhang Xiaofeng , Li Deyao , Pei Chengkui , Masuda Takeshi , Johansson Catrine , Wimalasena Virangika K. , Kim Yong , Hino Shinjiro , Usuki Shingo , Kawano Yawara , Samur Mehmet K. , Tai Yu-Tzu , Munshi Nikhil C. , Matsuoka Masao , Ohtsuki Sumio , Nakao Mitsuyoshi , Minami Takashi , Lauberth Shannon , Khan Javed , Oppermann Udo , Durbin Adam D. , Anderson Kenneth C. , Hideshima Teru , Qi Jun
Published: April 2023

Supplementary Figure S3 shows that JQKD82 have good activities against KDM5 in MM cells and in animal models.
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Authors: Rubinstein Samuel M. , Bhutani Divaya , Lynch Ryan C. , Hsu Chih-Yuan , Shyr Yu , Advani Shailesh , Mesa Ruben A. , Mishra Sanjay , Mundt Daniel P. , Shah Dimpy P. , Sica R. Alejandro , Stockerl-Goldstein Keith E. , Stratton Catherine , Weiss Matthias , Beeghly-Fadiel Alicia , Accordino Melissa , Assouline Sarit E. , Awosika Joy , Bakouny Ziad , Bashir Babar , Berg Stephanie , Bilen Mehmet Asim , Castellano Cecilia A. , Cogan Jacob C. , KC Devendra , Friese Christopher R. , Gupta Shilpa , Hausrath Daniel , Hwang Clara , Johnson Nathalie A. , Joshi Monika , Kasi Anup , Klein Elizabeth J. , Koshkin Vadim S. , Kuderer Nicole M. , Kwon Daniel H. , Labaki Chris , Latif Tahir , Lau Eric , Li Xuanyi , Lyman Gary H. , McKay Rana R. , Nagaraj Gayathri , Nizam Amanda , Nonato Taylor K. , Olszewski Adam J. , Polimera Hyma V. , Portuguese Andrew J. , Puc Matthew M. , Razavi Pedram , Rosovski Rachel , Schmidt Andrew , Shah Sumit A. , Shastri Aditi , Su Christopher , Torka Pallawi , Wise-Draper Trisha M. , Zubiri Leyre , Warner Jeremy L. , Thompson Michael A.
Published: April 2023

Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Supplementary Data from CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Authors: Shree Tanaya , Shankar Vishnu , Lohmeyer Julian J.K. , Czerwinski Debra K. , Schroers-Martin Joseph G. , Rodriguez Gladys M. , Beygi Sara , Kanegai Alyssa M. , Corbelli Karen S. , Gabriel Etelka , Kurtz David M. , Khodadoust Michael S. , Gupta Neel K. , Maeda Lauren S. , Advani Ranjana H. , Alizadeh Ash A. , Levy Ronald
Published: April 2023

Supplementary Data from CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Supplementary Data from Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia
Authors: Umeda Masayuki , Ma Jing , Huang Benjamin J. , Hagiwara Kohei , Westover Tamara , Abdelhamed Sherif , Barajas Juan M. , Thomas Melvin E. , Walsh Michael P. , Song Guangchun , Tian Liqing , Liu Yanling , Chen Xiaolong , Kolekar Pandurang , Tran Quang , Foy Scott G. , Maciaszek Jamie L. , Kleist Andrew B. , Leonti Amanda R. , Ju Bengsheng , Easton John , Wu Huiyun , Valentine Virginia , Valentine Marcus B. , Liu Yen-Chun , Ries Rhonda E. , Smith Jenny L. , Parganas Evan , Iacobucci Ilaria , Hiltenbrand Ryan , Miller Jonathan , Myers Jason R. , Rampersaud Evadnie , Rahbarinia Delaram , Rusch Michael , Wu Gang , Inaba Hiroto , Wang Yi-Cheng , Alonzo Todd A. , Downing James R. , Mullighan Charles G. , Pounds Stanley , Babu M. Madan , Zhang Jinghui , Rubnitz Jeffrey E. , Meshinchi Soheil , Ma Xiaotu , Klco Jeffery M.
Published: April 2023

Supplementary Data from Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia
Supplementary Table from Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia
Authors: Guess Tiffany , Potts Chad R. , Bhat Pawan , Cartailler Justin A. , Brooks Austin , Holt Clinton , Yenamandra Ashwini , Wheeler Ferrin C. , Savona Michael R. , Cartailler Jean-Philippe , Ferrell P. Brent
Published: April 2023

Supplementary Table from Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia
Supplementary Table from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
Authors: Dhodapkar Kavita M. , Cohen Adam D. , Kaushal Akhilesh , Garfall Alfred L. , Manalo Renee Julia , Carr Allison R. , McCachren Samuel S. , Stadtmauer Edward A. , Lacey Simon F. , Melenhorst J. Joseph , June Carl H. , Milone Michael C. , Dhodapkar Madhav V.
Published: April 2023

Supplementary Table from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
Supplementary Figure from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
Authors: Dhodapkar Kavita M. , Cohen Adam D. , Kaushal Akhilesh , Garfall Alfred L. , Manalo Renee Julia , Carr Allison R. , McCachren Samuel S. , Stadtmauer Edward A. , Lacey Simon F. , Melenhorst J. Joseph , June Carl H. , Milone Michael C. , Dhodapkar Madhav V.
Published: April 2023

Supplementary Figure from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
Supplementary Data from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
Authors: Dhodapkar Kavita M. , Cohen Adam D. , Kaushal Akhilesh , Garfall Alfred L. , Manalo Renee Julia , Carr Allison R. , McCachren Samuel S. , Stadtmauer Edward A. , Lacey Simon F. , Melenhorst J. Joseph , June Carl H. , Milone Michael C. , Dhodapkar Madhav V.
Published: April 2023

Supplementary Data from Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
Supplementary Figure from Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia
Authors: Guess Tiffany , Potts Chad R. , Bhat Pawan , Cartailler Justin A. , Brooks Austin , Holt Clinton , Yenamandra Ashwini , Wheeler Ferrin C. , Savona Michael R. , Cartailler Jean-Philippe , Ferrell P. Brent
Published: April 2023

Supplementary Figure from Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia
Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Authors: Wang Han , Chan Kathy Yuen Yee , Cheng Chi Keung , Ng Margaret H.L. , Lee Po Yi , Cheng Frankie Wai Tsoi , Lam Grace Kee See , Chow Tin Wai , Ha Shau Yin , Chiang Alan K.S. , Leung Wing Hang , Leung Anskar Y.H. , Wang Chi Chiu , Zhang Tao , Zhang Xiao-Bing , So Chi Chiu , Yuen Yuet Ping , Sun Qiwei , Zhang Chi , Xu Yaqun , Cheung John Tak Kit , Ng Wing Hei , Tang Patrick Ming-Kuen , Kang Wei , To Ka-Fai , Lee Wayne Yuk Wai , Wong Raymond S.M. , Poon Ellen Ngar Yun , Zhao Qi , Huang Junbin , Chen Chun , Yuen Patrick Man Pan , Li Chi-kong , Leung Alex Wing Kwan , Leung Kam Tong
Published: April 2023

Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Authors: Takeda June , Yoshida Kenichi , Nakagawa Masahiro M. , Nannya Yasuhito , Yoda Akinori , Saiki Ryunosuke , Ochi Yotaro , Zhao Lanying , Okuda Rurika , Qi Xingxing , Mori Takuto , Kon Ayana , Chiba Kenichi , Tanaka Hiroko , Shiraishi Yuichi , Kuo Ming-Chung , Kerr Cassandra M. , Nagata Yasunobu , Morishita Daisuke , Hiramoto Nobuhiro , Hangaishi Akira , Nakazawa Hideyuki , Ishiyama Ken , Miyano Satoru , Chiba Shigeru , Miyazaki Yasushi , Kitano Toshiyuki , Usuki Kensuke , Sezaki Nobuo , Tsurumi Hisashi , Miyawaki Shuichi , Maciejewski Jaroslaw P. , Ishikawa Takayuki , Ohyashiki Kazuma , Ganser Arnold , Heuser Michael , Thol Felicitas , Shih Lee-Yung , Takaori-Kondo Akifumi , Makishima Hideki , Ogawa Seishi
Published: April 2023

Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses
Authors: Gargiulo Ernesto , Viry Elodie , Morande Pablo Elías , Largeot Anne , Gonder Susanne , Xian Feng , Ioannou Nikolaos , Benzarti Mohaned , Kleine Borgmann Felix Bruno , Mittelbronn Michel , Dittmar Gunnar , Nazarov Petr V. , Meiser Johannes , Stamatopoulos Basile , Ramsay Alan G. , Moussay Etienne , Paggetti Jérôme
Published: April 2023

Supplemental Table S2 - Differential expression analysis of genes in leukemic or immune cells treated with sEV
Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses
Authors: Gargiulo Ernesto , Viry Elodie , Morande Pablo Elías , Largeot Anne , Gonder Susanne , Xian Feng , Ioannou Nikolaos , Benzarti Mohaned , Kleine Borgmann Felix Bruno , Mittelbronn Michel , Dittmar Gunnar , Nazarov Petr V. , Meiser Johannes , Stamatopoulos Basile , Ramsay Alan G. , Moussay Etienne , Paggetti Jérôme
Published: April 2023

Supplemental Table S1 - Proteins detected in sEV preparations or cells treated with sEV
Supplementary Methods and Figures from Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses
Authors: Gargiulo Ernesto , Viry Elodie , Morande Pablo Elías , Largeot Anne , Gonder Susanne , Xian Feng , Ioannou Nikolaos , Benzarti Mohaned , Kleine Borgmann Felix Bruno , Mittelbronn Michel , Dittmar Gunnar , Nazarov Petr V. , Meiser Johannes , Stamatopoulos Basile , Ramsay Alan G. , Moussay Etienne , Paggetti Jérôme
Published: April 2023

Supplementary Methods and Figures
Supplementary Table 5 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
Authors: Kodgule Rohan , Goldman Joshua W. , Monovich Alexander C. , Saari Travis , Aguilar Athalee R. , Hall Cody N. , Rajesh Niharika , Gupta Juhi , Chu Shih-Chun A. , Ye Li , Gurumurthy Aishwarya , Iyer Ashwin , Brown Noah A. , Chiang Mark Y. , Cieslik Marcin P. , Ryan Russell J.H.
Published: April 2023

Supplementary Table 5 annotates genome-wide candidate ETV6-repressed enhancers
Supplementary Table 4 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
Authors: Kodgule Rohan , Goldman Joshua W. , Monovich Alexander C. , Saari Travis , Aguilar Athalee R. , Hall Cody N. , Rajesh Niharika , Gupta Juhi , Chu Shih-Chun A. , Ye Li , Gurumurthy Aishwarya , Iyer Ashwin , Brown Noah A. , Chiang Mark Y. , Cieslik Marcin P. , Ryan Russell J.H.
Published: April 2023

Supplementary table 4 lists ETV6-regulated gene-enhancer linkages
Supplementary Table 2 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
Authors: Kodgule Rohan , Goldman Joshua W. , Monovich Alexander C. , Saari Travis , Aguilar Athalee R. , Hall Cody N. , Rajesh Niharika , Gupta Juhi , Chu Shih-Chun A. , Ye Li , Gurumurthy Aishwarya , Iyer Ashwin , Brown Noah A. , Chiang Mark Y. , Cieslik Marcin P. , Ryan Russell J.H.
Published: April 2023

Supplementary Table 2 details known and de novo motif analysis for distal acetylation clusters
Supplementary Table 1 from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
Authors: Kodgule Rohan , Goldman Joshua W. , Monovich Alexander C. , Saari Travis , Aguilar Athalee R. , Hall Cody N. , Rajesh Niharika , Gupta Juhi , Chu Shih-Chun A. , Ye Li , Gurumurthy Aishwarya , Iyer Ashwin , Brown Noah A. , Chiang Mark Y. , Cieslik Marcin P. , Ryan Russell J.H.
Published: April 2023

Supplementary Table 1 lists oligonucleotide sequences and cell line information
Supplementary Information file from ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
Authors: Kodgule Rohan , Goldman Joshua W. , Monovich Alexander C. , Saari Travis , Aguilar Athalee R. , Hall Cody N. , Rajesh Niharika , Gupta Juhi , Chu Shih-Chun A. , Ye Li , Gurumurthy Aishwarya , Iyer Ashwin , Brown Noah A. , Chiang Mark Y. , Cieslik Marcin P. , Ryan Russell J.H.
Published: April 2023

Contains Supplementary Figures 1-12 and additional information about Supplementary tables
Table S6 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Authors: Flümann Ruth , Hansen Julia , Pelzer Benedikt W. , Nieper Pascal , Lohmann Tim , Kisis Ilmars , Riet Tobias , Kohlhas Viktoria , Nguyen Phuong-Hien , Peifer Martin , Abedpour Nima , Bosco Graziella , Thomas Roman K. , Kochanek Moritz , Knüfer Jacqueline , Jonigkeit Lorenz , Beleggia Filippo , Holzem Alessandra , Büttner Reinhard , Lohneis Philipp , Meinel Jörn , Ortmann Monika , Persigehl Thorsten , Hallek Michael , Calado Dinis Pedro , Chmielewski Markus , Klein Sebastian , Göthert Joachim R. , Chapuy Bjoern , Zevnik Branko , Wunderlich F. Thomas , von Tresckow Bastian , Jachimowicz Ron D. , Melnick Ari M. , Reinhardt Hans Christian , Knittel Gero
Published: April 2023

Table S6 contains clinical parameters and sequencing results of human DLBCL samples.
Table S4 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Authors: Flümann Ruth , Hansen Julia , Pelzer Benedikt W. , Nieper Pascal , Lohmann Tim , Kisis Ilmars , Riet Tobias , Kohlhas Viktoria , Nguyen Phuong-Hien , Peifer Martin , Abedpour Nima , Bosco Graziella , Thomas Roman K. , Kochanek Moritz , Knüfer Jacqueline , Jonigkeit Lorenz , Beleggia Filippo , Holzem Alessandra , Büttner Reinhard , Lohneis Philipp , Meinel Jörn , Ortmann Monika , Persigehl Thorsten , Hallek Michael , Calado Dinis Pedro , Chmielewski Markus , Klein Sebastian , Göthert Joachim R. , Chapuy Bjoern , Zevnik Branko , Wunderlich F. Thomas , von Tresckow Bastian , Jachimowicz Ron D. , Melnick Ari M. , Reinhardt Hans Christian , Knittel Gero
Published: April 2023

Table S4 contains the individual mutations of PPMBC and MBC lymphomas.
Table S1 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Authors: Flümann Ruth , Hansen Julia , Pelzer Benedikt W. , Nieper Pascal , Lohmann Tim , Kisis Ilmars , Riet Tobias , Kohlhas Viktoria , Nguyen Phuong-Hien , Peifer Martin , Abedpour Nima , Bosco Graziella , Thomas Roman K. , Kochanek Moritz , Knüfer Jacqueline , Jonigkeit Lorenz , Beleggia Filippo , Holzem Alessandra , Büttner Reinhard , Lohneis Philipp , Meinel Jörn , Ortmann Monika , Persigehl Thorsten , Hallek Michael , Calado Dinis Pedro , Chmielewski Markus , Klein Sebastian , Göthert Joachim R. , Chapuy Bjoern , Zevnik Branko , Wunderlich F. Thomas , von Tresckow Bastian , Jachimowicz Ron D. , Melnick Ari M. , Reinhardt Hans Christian , Knittel Gero
Published: April 2023

Table S1 contains the p values of comparisons of the V gene usage in non-malignant GC B cells between the individual genotypes. These comparisons were done on the family, gene and allele level. V usage was compared for all BCR sequences as well as for isotype subsets.
Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
Authors: Garfall Alfred L. , Cohen Adam D. , Susanibar-Adaniya Sandra P. , Hwang Wei-Ting , Vogl Dan T. , Waxman Adam J. , Lacey Simon F. , Gonzalez Vanessa E. , Fraietta Joseph A. , Gupta Minnal , Kulikovskaya Irina , Tian Lifeng , Chen Fang , Koterba Natalka , Bartoszek Robert L. , Patchin Margaret , Xu Rong , Plesa Gabriela , Siegel Don L. , Brennan Andrea , Nelson Anne Marie , Ferthio Regina , Cosey Angela , Shea Kim-Marie , Leskowitz Rachel , Four Megan , Wilson Wesley V. , Miao Fei , Lancaster Eric , Carreno Beatriz M. , Linette Gerald P. , Hexner Elizabeth O. , Young Regina M. , Bu Dexiu , Mansfield Keith G. , Brogdon Jennifer L. , June Carl H. , Milone Michael C. , Stadtmauer Edward A.
Published: April 2023

Supplemental tables: (1) Subject characteristics. (2) Cytogenetic profiles and high-risk features. (3) Prior treatment exposures and refractoriness. (4) CAR T cell product characteristics. (5) Products that did not meet target dose. (6) Adverse events of grade 3-4. (7) Cytokine release syndrome and ICANS. (8). Maintenance therapy. Supplemental Figures: (1) Study schematic and subject disposition, (2) Correlates of manufacturing success, (3) Hematopoietic recovery, (4) Post-infusion T cell phenotypes, (5) Correlates of in vivo expansion and manufacturing success, (6) Late post-infusion CAR T cell re-expansion, (7) Soluble BCMA, (8) Late-onset clinical responses, (9) MM cell BCMA expression, (10) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA monotherapy patients, (11) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA + huCART19 combination therapy patients, (12) Sustained post-treatment SOX2-specific T-cell responses.
Supplementary Figures S1-S10 from Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis
Authors: Kim Rathana , Bergugnat Hugo , Larcher Lise , Duchmann Matthieu , Passet Marie , Gachet Stéphanie , Cuccuini Wendy , Lafage-Pochitaloff Marina , Pastoret Cédric , Grardel Nathalie , Asnafi Vahid , Schäfer Beat W. , Delabesse Eric , Itzykson Raphaël , Adès Lionel , Hicheri Yosr , Chalandon Yves , Graux Carlos , Chevallier Patrice , Hunault Mathilde , Leguay Thibaut , Huguet Françoise , Lhéritier Véronique , Dombret Hervé , Soulier Jean , Rousselot Philippe , Boissel Nicolas , Clappier Emmanuelle
Published: April 2023

Supplementary figure 1. Sequencing-based analysis of CNA and LOH in adult LH-ALL.
Supplementary figure 2. Representation of mutations in the frequent targeted genes in adult LH-ALL.
Supplementary figure 3. Longitudinal assessment of TP53-mutant cell fraction as determined by ddPCR along with clonal IG/TR-based MRD quantification in three patients with undetectable TP53 mutation at remission.
Supplementary figure 4. Merged single-cell analysis of cell-surface markers by ADT-sequencing of remission samples from three LH-ALL patients.
Supplementary figure 5. Individual single-cell analyses of cell-surface markers by ADT-sequencing of remission samples from three LH-ALL patients.
Supplementary figure 6. Individual analyses of single-cell immunophenotyping and genotyping of remission samples from three LH-ALL patients.
Supplementary figure 7. Evaluation of allelic dropout rate on heterozygous single nucleotide polymorphism (SNPs) in remission samples.
Supplementary figure 8. Individual single-cell analysis of cell-surface markers by ADT-sequencing of diagnosis samples from three LH-ALL patients.
Supplementary figure 9. Single-cell genotyping of heterozygous SNPs allowing LOH assessment in diagnosis samples from three LH-ALL patients.
Supplementary Figure 10. Distribution of single-cell genotypes of two LH-ALL patients with persistent TP53 and JAK2 (EI_046) or DNMT3A (EI_035) mutations in remission samples.
Figure S3 from Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC
Authors: Faux Maree C. , Weinstock Janet , Gogos Sophia , Prato Emma , Azimpour Alexander I. , O'Keefe Ryan , Cathcart-King Yasmin , Garnham Alexandra L. , Ernst Matthias , Preaudet Adele , Christie Michael , Putoczki Tracy L. , Buchert Michael , Burgess Antony W.
Published: April 2023

Histology and immunohistochemical analysis of beta-catenin in adenomas from treated Dclk1Cre/+;Apcfl/fl mice.
Figure S2 from Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC
Authors: Faux Maree C. , Weinstock Janet , Gogos Sophia , Prato Emma , Azimpour Alexander I. , O'Keefe Ryan , Cathcart-King Yasmin , Garnham Alexandra L. , Ernst Matthias , Preaudet Adele , Christie Michael , Putoczki Tracy L. , Buchert Michael , Burgess Antony W.
Published: April 2023

Adenoma tumour development in Apcmin/+ and Dclk1Cre/+;Apcfl/fl mice
Figure S1 from Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC
Authors: Faux Maree C. , Weinstock Janet , Gogos Sophia , Prato Emma , Azimpour Alexander I. , O'Keefe Ryan , Cathcart-King Yasmin , Garnham Alexandra L. , Ernst Matthias , Preaudet Adele , Christie Michael , Putoczki Tracy L. , Buchert Michael , Burgess Antony W.
Published: April 2023

Xgal and DCLK1 staining of colon crypts from DCLK1-CreERT2 BAC transgenic mice
Supplementary Table 1 from Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Wang Yu , Xu Yaomin , Sun Xiaopeng , Bejan Cosmin A. , Gonzalez-Ericsson Paula I. , Nunnery Sara , Bergman Riley E. , Donaldson Joshua , Guerrero-Zotano Angel L. , Massa Chiara , Seliger Barbara , Sanders Melinda , Mayer Ingrid A. , Balko Justin M.
Published: April 2023

Differentially expressed genes between pCR and RD samples.
Supplementary Tables 1-5 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Authors: Marastoni Stefano , Madariaga Ainhoa , Pesic Aleksandra , Nair Sree Narayanan , Li Zhu Juan , Shalev Zvi , Ketela Troy , Colombo Ilaria , Mandilaras Victoria , Cabanero Michael , Bruce Jeff P. , Li Xuan , Garg Swati , Wang Lisa , Chen Eric X. , Gill Sarbjot , Dhani Neesha C. , Zhang Wenjiang , Pintilie Melania , Bowering Valerie , Koritzinsky Marianne , Rottapel Robert , Wouters Bradly G. , Oza Amit M. , Joshua Anthony M. , Lheureux Stephanie
Published: April 2023

Supplementary Tables 1 and 2 show respectively the fold change of lysosomal function and size in treated sensitive/resistant cells obtained by mixed effect modelling. Supplementary Table 3 shows patients enrolled per dose-level (DL) and dose limiting toxicities (DLTs). Supplementary Tables 4 and 5 show the summary of all and treatment related adverse effects.
Supplementary File 2 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Authors: Marastoni Stefano , Madariaga Ainhoa , Pesic Aleksandra , Nair Sree Narayanan , Li Zhu Juan , Shalev Zvi , Ketela Troy , Colombo Ilaria , Mandilaras Victoria , Cabanero Michael , Bruce Jeff P. , Li Xuan , Garg Swati , Wang Lisa , Chen Eric X. , Gill Sarbjot , Dhani Neesha C. , Zhang Wenjiang , Pintilie Melania , Bowering Valerie , Koritzinsky Marianne , Rottapel Robert , Wouters Bradly G. , Oza Amit M. , Joshua Anthony M. , Lheureux Stephanie
Published: April 2023

CRISPR screen TOV1946. Results of the Itra sensitizing CRISPR screen on the TOV1946 cell line using drugZ algorithm.
Supplementary Figures 1-7 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Authors: Marastoni Stefano , Madariaga Ainhoa , Pesic Aleksandra , Nair Sree Narayanan , Li Zhu Juan , Shalev Zvi , Ketela Troy , Colombo Ilaria , Mandilaras Victoria , Cabanero Michael , Bruce Jeff P. , Li Xuan , Garg Swati , Wang Lisa , Chen Eric X. , Gill Sarbjot , Dhani Neesha C. , Zhang Wenjiang , Pintilie Melania , Bowering Valerie , Koritzinsky Marianne , Rottapel Robert , Wouters Bradly G. , Oza Amit M. , Joshua Anthony M. , Lheureux Stephanie
Published: April 2023

Supplementary Figure 1: Itra dose response in ovarian cancer cell lines. - Supplementary Figure 2: Analysis on ovarian cancer cell lines used in the Itra-sensitizing CRISPR screen (OVCAR5 and TOV1946). - Supplementary Figure 3: c18orf8 and VPS54 Knockout effects on the TOV1946 cell line. - Supplementary Figure 4: Itra+CQ dose responses. - Supplementary Figure 5: 5/10 uM CQ response and apoptosis assay results. - Supplementary Figure 6: Itra+CQ dose response in c18orf8 and VPS54 knockout cells and calculation of synergy scores. - Supplementary Figure 7: Intratumoural Itra/CQ detection and Ki-67 analysis in patient samples.
Clinical Trial Protocol from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Authors: Marastoni Stefano , Madariaga Ainhoa , Pesic Aleksandra , Nair Sree Narayanan , Li Zhu Juan , Shalev Zvi , Ketela Troy , Colombo Ilaria , Mandilaras Victoria , Cabanero Michael , Bruce Jeff P. , Li Xuan , Garg Swati , Wang Lisa , Chen Eric X. , Gill Sarbjot , Dhani Neesha C. , Zhang Wenjiang , Pintilie Melania , Bowering Valerie , Koritzinsky Marianne , Rottapel Robert , Wouters Bradly G. , Oza Amit M. , Joshua Anthony M. , Lheureux Stephanie
Published: April 2023

Detailed protocol of the HYDRA-1 (NCT03081702) Trial. TITLE: A phase I/II trial investigating the tolerability, toxicity and efficacy of hydroxychloroquine and itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-1 study).
Supplementary Table 9 from Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors
Authors: George Joshy , Chen Yaohui , Abdelfattah Nourhan , Yamamoto Keiko , Gallup Thomas D. , Adamson Scott I. , Rybinski Brad , Srivastava Anuj , Kumar Parveen , Lee Min Gyu , Baskin David S. , Jiang Wen , Choi Jong Min , Flavahan William , Chuang Jeffrey H. , Kim Betty Y.S. , Xu Jiaqiong , Jung Sung Yun , Yun Kyuson
Published: April 2023

Supplementary Table 9: Differentially expressed proteins in LDE vs. control treated Ptch;p53 SI-CSC and SD-CSC tumors
Supplementary Table 8 from Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors
Authors: George Joshy , Chen Yaohui , Abdelfattah Nourhan , Yamamoto Keiko , Gallup Thomas D. , Adamson Scott I. , Rybinski Brad , Srivastava Anuj , Kumar Parveen , Lee Min Gyu , Baskin David S. , Jiang Wen , Choi Jong Min , Flavahan William , Chuang Jeffrey H. , Kim Betty Y.S. , Xu Jiaqiong , Jung Sung Yun , Yun Kyuson
Published: April 2023

Supplementary Table 8: DEG in LDE vs control in SD-CSC Ptch;p53 tumors
Supplementary Table 3 from Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors
Authors: George Joshy , Chen Yaohui , Abdelfattah Nourhan , Yamamoto Keiko , Gallup Thomas D. , Adamson Scott I. , Rybinski Brad , Srivastava Anuj , Kumar Parveen , Lee Min Gyu , Baskin David S. , Jiang Wen , Choi Jong Min , Flavahan William , Chuang Jeffrey H. , Kim Betty Y.S. , Xu Jiaqiong , Jung Sung Yun , Yun Kyuson
Published: April 2023

Supplementary Table 3: Mutational profiles for Ptch;p53 SD-CSC tumors
Supplementary Figures and Tables 1-2 from Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors
Authors: George Joshy , Chen Yaohui , Abdelfattah Nourhan , Yamamoto Keiko , Gallup Thomas D. , Adamson Scott I. , Rybinski Brad , Srivastava Anuj , Kumar Parveen , Lee Min Gyu , Baskin David S. , Jiang Wen , Choi Jong Min , Flavahan William , Chuang Jeffrey H. , Kim Betty Y.S. , Xu Jiaqiong , Jung Sung Yun , Yun Kyuson
Published: April 2023

Supplementary figures and Tables 1 & 2
Table S4 from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
Authors: Vergato Cameron , Doshi Kshama A. , Roblyer Darren , Waxman David J.
Published: April 2023

Table S4. RNAseq analysis of 4T1 tumors, with vs without metronomic CPA treatment.
Table S3 from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
Authors: Vergato Cameron , Doshi Kshama A. , Roblyer Darren , Waxman David J.
Published: April 2023

Table S3. RNAseq library sequencing stats.
Supplementary Figures S1-S9 from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
Authors: Vergato Cameron , Doshi Kshama A. , Roblyer Darren , Waxman David J.
Published: April 2023

Figures S1-S9 with detailed legends:

Fig. S1. Hormone receptor and related gene expression patterns in E0771 and 4T1 tumor cells. (A) Expression in E0771 cells and E0771 tumors, based on RNAseq data included in Table S1 and Table S5; and (B) Expression in 4T1 cells and 4T1 tumors.(C) Summary of hormone receptor expression patterns.

Fig. S2. Gene-specific qPCR primer sequences, amplicon length and percent GC content

Fig. S3. Dose-dependence of drug sensitivity of cultured 4T1, E0771 and B16F10 cells. Shown are viability assays determined in MTS assays.

Fig. S4. ISG induction by 4HC-conditioned culture medium.

Fig. S5. Verification of anti-IFNAR-1 antibody inhibitory activity.

Fig. S6. E0771 tumor growth curves and qPCR analysis of metronomic-CPA in vivo dose response data.

Fig. S7. Representative FACS analysis of blood from CPA-treated mice, with and without anti-CD8a antibody treatment.

Fig. S8. Circulating CD8 T-cells for CPA-treated mice with and without anti-CD8a antibody.

Fig. S9. FACS analysis of blood and tumors from mice given metronomic CPA treatment with and without anti-IFNAR1 antibody.
Supplementary Video S1 from Increased Microtubule Growth Triggered by Microvesicle-mediated Paracrine Signaling is Required for Melanoma Cancer Cell Invasion
Authors: Pudelko Karoline , Wieland Angela , Hennecke Magdalena , Räschle Markus , Bastians Holger
Published: April 2023

The supplementary Movie S1 shows an example movie displaying the detection of EB3-GFP in a living interphase melanoma cell,
Supplementary Data S1 from Replication Stress Defines Distinct Molecular Subtypes Across Cancers
Authors: Takahashi Nobuyuki , Kim Sehyun , Schultz Christopher W. , Rajapakse Vinodh N. , Zhang Yang , Redon Christophe E. , Fu Haiqing , Pongor Lorinc , Kumar Suresh , Pommier Yves , Aladjem Mirit I. , Thomas Anish
Published: April 2023

Supplementary Data
Supplementary Table S1 from Increased Microtubule Growth Triggered by Microvesicle-mediated Paracrine Signaling is Required for Melanoma Cancer Cell Invasion
Authors: Pudelko Karoline , Wieland Angela , Hennecke Magdalena , Räschle Markus , Bastians Holger
Published: April 2023

The supplementary Table S1 provides the results of the mass spectrometry results comparing protein content of microvesicles from melanoma cells with or without PLK4 overexpression.
Figure S5 from Increased Microtubule Growth Triggered by Microvesicle-mediated Paracrine Signaling is Required for Melanoma Cancer Cell Invasion
Authors: Pudelko Karoline , Wieland Angela , Hennecke Magdalena , Räschle Markus , Bastians Holger
Published: April 2023

Figure S5 shows that HER2 inhibition does not affect cell cycle progression or cell death and HER2 overexpression is not sufficient to significantly increase spheroid outgrowth in 3D matrices.
Figure S4 from Increased Microtubule Growth Triggered by Microvesicle-mediated Paracrine Signaling is Required for Melanoma Cancer Cell Invasion
Authors: Pudelko Karoline , Wieland Angela , Hennecke Magdalena , Räschle Markus , Bastians Holger
Published: April 2023

Figure S4 shows that microvesicles from non-invasive melanoma cells with PLK4 overexpression increase microtubule growth rates in recipient cells.
Figure S2 from Increased Microtubule Growth Triggered by Microvesicle-mediated Paracrine Signaling is Required for Melanoma Cancer Cell Invasion
Authors: Pudelko Karoline , Wieland Angela , Hennecke Magdalena , Räschle Markus , Bastians Holger
Published: April 2023

Figure S2 shows that CKAP5, STIL or PLK4 overexpression is not sufficient to significantly increase spheroid outgrowth in 3D matrices.
Figure S1 from Increased Microtubule Growth Triggered by Microvesicle-mediated Paracrine Signaling is Required for Melanoma Cancer Cell Invasion
Authors: Pudelko Karoline , Wieland Angela , Hennecke Magdalena , Räschle Markus , Bastians Holger
Published: April 2023

Figure S1 shows that low-dose Taxol or CKAP5 siRNA treatment does not induce cell cycle alterations or cell death while CKAP overexpression increases microtubule growth rates.
Supplementary Tables 1-7, Figures 1-3 from Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma
Authors: Hamlin Paul A. , Musteata Vasile , Park Steven I. , Burnett Christine , Dabovic Kristina , Strack Thomas , Williams Eric T. , Anand Banmeet S. , Higgins Jack P. , Persky Daniel O.
Published: April 2023

Supplementary Table 1. Additional Study Eligibility Criteria. Supplementary Table 2. Pharmacokinetic Serum Sample Collection. Supplementary Table 3. Summary of Adverse Events and Discontinuations. Supplementary Table 4. Summary of Serum MT-3724 PK Parameters by Treatment on Cycle 1 Day 1. Supplementary Table 5. Summary of Serum MT-3724 PK Parameters by Treatment on Cycle 1 Day 12. Supplementary Table 6. Best Overall Response, Objective Response Rate, and Disease Control Rate (FAS). Supplementary Table 7. Summary of ADA Incidence by Actual Dose. Supplementary Figure 1. Study Design for Dose Escalation and Dose Expansion. Supplementary Figure 2. CONSORT diagram. Supplementary Figure 3. Individual CD19+ Nadir Percent Change from Baseline.
Supplementary Tables S1-S7, Figures S1-S4 from Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer
Authors: Pellinen Teijo , Sandeman Kevin , Blom Sami , Turkki Riku , Hemmes Annabrita , Välimäki Katja , Eineluoto Juho , Kenttämies Anu , Nordling Stig , Kallioniemi Olli , Rannikko Antti , Mirtti Tuomas
Published: April 2023

Supplementary Tables S1-S7. Supplementary Figures S1-S4.
Figure SF2 from Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer
Authors: Morris Van K. , Overman Michael J. , Lam Michael , Parseghian Christine M. , Johnson Benny , Dasari Arvind , Raghav Kanwal , Kee Bryan K. , Huey Ryan , Wolff Robert A. , Shen John Paul , Li June , Zorrilla Isabel , Tzeng Ching-Wei D. , Tran Cao Hop S. , Chun Yun Shin , Newhook Timothy E. , Vauthey Nicolas , Duose Dzifa , Luthra Raja , Haymaker Cara , Kopetz Scott
Published: April 2023

Supplemental Figure S2
Supplementary Tables S1-S4 from Prospective Associations of Hemoglobin A1c and c-peptide with Risk of Diabetes-related Cancers in the Cancer Prevention Study-II Nutrition Cohort
Authors: Campbell Peter T. , Newton Christina C. , Jacobs Eric J. , McCullough Marjorie L. , Wang Ying , Rees-Punia Erika , Guinter Mark A. , Murphy Neil , Koshiol Jill , Dehal Ahmed N. , Rohan Thomas , Strickler Howard , Petrick Jessica , Gunter Marc , Zhang Xuehong , McGlynn Katherine A. , Pollak Michael , Patel Alpa V. , Gapstur Susan M.
Published: April 2023

Supplemental Table 1 - Association of self-reported T2DM at blood draw with risk of all-cancers combined and separately in CPS-II LifeLink participants; Supplemental Table 2 - Association BMI per 5 kg/m2 at blood draw with risk of all-cancers combined and separately in CPS-II LifeLink participants. Excludes those with BMI <18.5 kg/m2; Supplementary Table 3 - Associations of c-peptide with risk of all cancers combined and for the specific cancers of interest by sex in the CPS-II LifeLink cohort; Supplementary Table 4 - Associations of HbA1c with risk of all cancers combined and for the specific cancers of interest by sex in the CPS-II LifeLink cohort.
Supplementary Figures S1-S10 from Ribonuclease H2 Subunit A Preserves Genomic Integrity and Promotes Prostate Cancer Progression
Authors: Kimura Naoki , Takayama Ken-ichi , Yamada Yuta , Kume Haruki , Fujimura Tetsuya , Inoue Satoshi
Published: April 2023

Supplementary Figure S1. Loss of RNASEH2A expression repressed CRPC cell growth and migration. Supplementary Figure S2. RNASEH2A inhibits DNA damage response and apoptosis in PC cells.

Supplementary Figure S3. siRNASEH2A promotes p53 expression in LNCaP. Supplementary Figure S4. RNASEH2A positively regulates AR expression and downstream signaling. Supplementary Figure S5. RNASEH2A positively regulates AR-mediated cell growth. Supplementary Figure S6. Knockdown of p53 induced AR expression and cell growth. Supplementary Figure S7. DNA methylation is not significantly affected by RNASEH2A knockdown.

Supplementary Figure S8. Each RNASEH2 subunit gene expression in PC by using public database. Supplementary Figure S9. The effect of RNase H2 i treatment on LNCaP cells. Supplementary Figure S10. No apparent toxic effect was observed in tissues of mice treated with RNase H2 i.
Supplementary Table TS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
Authors: Yao Lijun , Jayasinghe Reyka G. , Lee Brian H. , Bhasin Swati S. , Pilcher William , Doxie Deon Bryant , Gonzalez-Kozlova Edgar , Dasari Surendra , Fiala Mark A. , Pita-Juarez Yered , Strausbauch Michael , Kelly Geoffrey , Thomas Beena E. , Kumar Shaji K. , Cho Hearn Jay , Anderson Emilie , Wendl Michael C. , Dawson Travis , D'souza Darwin , Oh Stephen T. , Cheloni Giulia , Li Ying , DiPersio John F. , Rahman Adeeb H. , Dhodapkar Kavita M. , Kim-Schulze Seunghee , Vij Ravi , Vlachos Ioannis S. , Mehr Shaadi , Hamilton Mark , Auclair Daniel , Kourelis Taxiarchis , Avigan David , Dhodapkar Madhav V. , Gnjatic Sacha , Bhasin Manoj K. , Ding Li
Published: April 2023

supplementary table 1 shows cell type annotation markers, clinical information of patients, cross-technique comparison of cell subset abundance and expression of cell type marker genes in CITE-seq and CyTOF
Table ST2 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Authors: Kuboki Yasutoshi , Shimizu Toshio , Yonemori Kan , Kojima Takashi , Kondo Shunsuke , Koganemaru Shigehiro , Iwasa Satoru , Harano Kenichi , Koyama Takafumi , Lu Vickie , Zhou Xiaofei , Niu Huifeng , Yanai Tomoko , Garcia-Ribas Ignacio , Doi Toshihiko , Yamamoto Noboru
Published: April 2023

Summary of best response to treatment per investigator’s assessment.
Supplementary Methods SM1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Authors: Kuboki Yasutoshi , Shimizu Toshio , Yonemori Kan , Kojima Takashi , Kondo Shunsuke , Koganemaru Shigehiro , Iwasa Satoru , Harano Kenichi , Koyama Takafumi , Lu Vickie , Zhou Xiaofei , Niu Huifeng , Yanai Tomoko , Garcia-Ribas Ignacio , Doi Toshihiko , Yamamoto Noboru
Published: April 2023

Supplementary methods including inclusion and exclusion criteria
Supplementary Table S4 from A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
Authors: Hidalgo Manuel , Garcia-Carbonero Rocio , Lim Kian-Huat , Messersmith Wells A. , Garrido-Laguna Ignacio , Borazanci Erkut , Lowy Andrew M. , Medina Rodriguez Laura , Laheru Daniel , Salvador-Barbero Beatriz , Malumbres Marcos , Shields David J. , Grossman Joseph E. , Huang Xin , Tammaro Meggan , Martini Jean-François , Yu Yanke , Kern Kenneth , Macarulla Teresa
Published: April 2023

Palbociclib Pharmacokinetic Parameters in the MTD Cohort.
Supplementary Table S3 from A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
Authors: Hidalgo Manuel , Garcia-Carbonero Rocio , Lim Kian-Huat , Messersmith Wells A. , Garrido-Laguna Ignacio , Borazanci Erkut , Lowy Andrew M. , Medina Rodriguez Laura , Laheru Daniel , Salvador-Barbero Beatriz , Malumbres Marcos , Shields David J. , Grossman Joseph E. , Huang Xin , Tammaro Meggan , Martini Jean-François , Yu Yanke , Kern Kenneth , Macarulla Teresa
Published: April 2023

Supplementary Table S3 from A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
Figure SF3 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Authors: Kuboki Yasutoshi , Shimizu Toshio , Yonemori Kan , Kojima Takashi , Kondo Shunsuke , Koganemaru Shigehiro , Iwasa Satoru , Harano Kenichi , Koyama Takafumi , Lu Vickie , Zhou Xiaofei , Niu Huifeng , Yanai Tomoko , Garcia-Ribas Ignacio , Doi Toshihiko , Yamamoto Noboru
Published: April 2023

Mean (+StDev) plasma concentration-time profiles of TAK-931 in patients after: (A) a single dose or (B) multiple doses of TAK-931 at cycle 1, day 1 by schedule (linear scale) in the pharmacokinetic-evaluable population.
Figure SF1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Authors: Kuboki Yasutoshi , Shimizu Toshio , Yonemori Kan , Kojima Takashi , Kondo Shunsuke , Koganemaru Shigehiro , Iwasa Satoru , Harano Kenichi , Koyama Takafumi , Lu Vickie , Zhou Xiaofei , Niu Huifeng , Yanai Tomoko , Garcia-Ribas Ignacio , Doi Toshihiko , Yamamoto Noboru
Published: April 2023

Dosing, PK, and pharmacodynamic sampling schedules.
Supplementary Table S1 from A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
Authors: Hidalgo Manuel , Garcia-Carbonero Rocio , Lim Kian-Huat , Messersmith Wells A. , Garrido-Laguna Ignacio , Borazanci Erkut , Lowy Andrew M. , Medina Rodriguez Laura , Laheru Daniel , Salvador-Barbero Beatriz , Malumbres Marcos , Shields David J. , Grossman Joseph E. , Huang Xin , Tammaro Meggan , Martini Jean-François , Yu Yanke , Kern Kenneth , Macarulla Teresa
Published: April 2023

Supplementary Table S1 from A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
Supplementary Tables 1-3, Figures 1-3 from Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium
Authors: Barber Emma L. , Chen Siqi , Pineda Mario Javier , Robertson Sharon E. , Hill Emily K. , Teoh Deanna , Schilder Jeanne , O'Shea Kaitlyn L. , Kocherginsky Masha , Zhang Bin , Matei Daniela
Published: April 2023

Supplementary Table 1. Treatment discontinuation due to AE. Supplementary Table 2. Worst grade toxicity related to pembrolizumab in >=5% of patients. Supplementary Table 3. PDL1 staining by objective responder status. Supplementary Figure S1. CONSORT diagram illustrates distribution of patients after enrollment. Supplementary Figure S2. Gating strategies for the main immune populations in PBMC. Supplementary Figure S3. The FlowSOM tree for the PBMC collected at C1D1 showing unsupervised metaclustering.
Figure S3 from Under-Representation of Racial Groups in Genomics Studies of Gastroenteropancreatic Neuroendocrine Neoplasms
Authors: Herring Brendon R. , Bonner Andrew , Guenter Rachael E. , Vickers Selwyn , Yates Clayton , Lee Goo , Dhall Deepti , Chen Herbert , Rose J. Bart
Published: April 2023

Composition of Black and White patient cohorts from the AACR GENIE dataset by sequencing assay ID’s, depicted by raw subject numbers (Left) and by % composition (Right). Only sequencing assays that included both Black and White patients were considered.
Figure S1 from Under-Representation of Racial Groups in Genomics Studies of Gastroenteropancreatic Neuroendocrine Neoplasms
Authors: Herring Brendon R. , Bonner Andrew , Guenter Rachael E. , Vickers Selwyn , Yates Clayton , Lee Goo , Dhall Deepti , Chen Herbert , Rose J. Bart
Published: April 2023

Assays used to analyze biomolecules in the 16 studies of GEP-NENs that reported patient race.
Supplementary Tables S1-S7 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
Authors: Chen Hao , Cresswell Gregory M. , Libring Sarah , Ayers Mitchell G. , Miao Jinmin , Zhang Zhong-Yin , Solorio Luis , Ratliff Timothy L. , Wendt Michael K.
Published: April 2023

These are supplementary tables to provide detailed information about the materials used in the study including cell, culture conditions, growth factors, inhibitors, and antibodies.
Supplementary Data SD1 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
Authors: McKenzie Duncan R. , Graham Rosalind , Lechmere Thomas , Domingo-Vila Clara , Alaguthurai Thanussuyah , Arman Celeste , Pollock Emily , Gousis Charalampos , Kakkassery Helen , Carpenter Esme , Kurshan Ashwini , Vidler Jennifer , Kulasekararaj Austin , Patten Piers , North Bernard V. , Tree Timothy , Doores Katie J. , Hayday Adrian C. , Irshad Sheeba
Published: April 2023

Supplementary Table & Figure Legends
Supplementary Information SI1 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
Authors: Chen Hao , Cresswell Gregory M. , Libring Sarah , Ayers Mitchell G. , Miao Jinmin , Zhang Zhong-Yin , Solorio Luis , Ratliff Timothy L. , Wendt Michael K.
Published: April 2023

This is the code information for publicly available data analysis.
Figure S4 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
Authors: McKenzie Duncan R. , Graham Rosalind , Lechmere Thomas , Domingo-Vila Clara , Alaguthurai Thanussuyah , Arman Celeste , Pollock Emily , Gousis Charalampos , Kakkassery Helen , Carpenter Esme , Kurshan Ashwini , Vidler Jennifer , Kulasekararaj Austin , Patten Piers , North Bernard V. , Tree Timothy , Doores Katie J. , Hayday Adrian C. , Irshad Sheeba
Published: April 2023

S4. Local and systemic effects reported within 30 days after 3rd dose of COVID-19 vaccine in patients with solid and haematological cancers and healthy controls.
Supplementary Figure S9 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
Authors: Chen Hao , Cresswell Gregory M. , Libring Sarah , Ayers Mitchell G. , Miao Jinmin , Zhang Zhong-Yin , Solorio Luis , Ratliff Timothy L. , Wendt Michael K.
Published: April 2023

Representative dot plots for data shown in figure 4B-C and additional exhaustion marker analysis of CD4+ T cells in mice bearing SHP2 manipulated 4T1 metastases.
Figure S1 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
Authors: McKenzie Duncan R. , Graham Rosalind , Lechmere Thomas , Domingo-Vila Clara , Alaguthurai Thanussuyah , Arman Celeste , Pollock Emily , Gousis Charalampos , Kakkassery Helen , Carpenter Esme , Kurshan Ashwini , Vidler Jennifer , Kulasekararaj Austin , Patten Piers , North Bernard V. , Tree Timothy , Doores Katie J. , Hayday Adrian C. , Irshad Sheeba
Published: April 2023

S1. Waning serological responses to SARS-CoV-2 vaccination.
Supplementary Figure S3 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
Authors: Chen Hao , Cresswell Gregory M. , Libring Sarah , Ayers Mitchell G. , Miao Jinmin , Zhang Zhong-Yin , Solorio Luis , Ratliff Timothy L. , Wendt Michael K.
Published: April 2023

Corresponding representative dot plots for the quantification in figure 2A and additional T cell composition analysis in the study of D2.A1 model.